ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 946

Phase 1 Study of Immunotherapy Using Autoantigen-Loaded Dendritic Cells in Patients with Anti-Citrullinated Peptide Antigen Positive Rheumatoid Arthritis

Young Bin Joo1, Jun-Eui Park2, Chan-Bum Choi3, Jeongim Choi1, Jin-ah Jang2, Minkyu Heo2, Hak-yeop Kim2, Hye-Soon Lee4, Yong-Soo Bae5 and Sang-Cheol Bae1, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2JW CreaGene Research Institute, JWCreaGene Inc., Seongnam-si, South Korea, 3Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 41Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 53Department of Biological Science, Sungkyunkwan University, Suwon, South Korea

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Dendritic cells, rheumatoid arthritis (RA) and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy II: Novel Therapies in Rheumatoid Arthritis - Early in Development

Session Type: Abstract Submissions (ACR)

Background/Purpose

To date, no dendritic cell (DC) immunotherapy has been shown to give a benefit in patients with rheumatoid arthritis (RA). In this prospective phase I study, we evaluated the safety and clinical efficacy of autologous tolerogenic dendritic cell (DC) administration (CreaVax-RA) in patients with RA.

Methods

Twelve RA patients (six for low dose vaccination, 0.5 x 107 cells/injection and remaining six for high dose vaccination, 1.5 x 107 cells/injection) were administrated five times at 2 to 4 week intervals subcutaneously (around inguinal lymph nodes) with each CreaVax-RA, autologous semi-mature DCs pulsed with recombinant PAD4, RA33, citrullinated-filaggrin (cit-FLG) and vimentin antigens. Safety and clinical benefits together with associated immune responses were evaluated as primary and secondary outcomes, respectively, at 14 and 24 weeks after first administration. The major clinical outcomes were assessed by European League Against Rheumatism (EULAR) response.

Results

Among a total of 12 adverse events (AEs) in eight patients, 11 events (91.7%) were restricted in patients treated with low dose (0.5 x 107 cells/inj) while 1 event in patients with high dose (1.5 x 107 cells/inj). All of the AEs were grade 1 or 2 without over grade 3 AE. In ELISPOT assay, the number of IFN-γ-secreting T cells decreased in 91.7% (n = 11/12). The level of antigen-specific autoantibodies significantly decreased in 55.6% (n=5/9) among the autoantibody-positive patients against more than one autoantigen (p < 0.001). The percentage of patients who achieved a good-to-moderate EULAR response ranged over 58.3% (n = 7/12) at 14 weeks after initial administration. The response rate was much higher in high dose group than in low dose group (83.3% vs 33.3%, respectively). The patients without any autoantibodies showed no clinical efficacy

Conclusion

DC administration (CreaVax-RA) was safe and well tolerated in patients with RA in the present phase I study. Preliminary, but clinical outcomes were in good agreement with doses and immune responses. These phase I results warrant further clinical study of high dose CreaVax-RA (1.5 x 107/inj) in patients with RA.

Trial registration: CRiS KCT0000035

Clinical Research Information Service [Internet]; Osong (Chungchengbuk-do): Korea Centers for Disease Control and Prevention Ministry of Health and Welfare (Republic of Korea); 2010;KCT0000035; A phase I, open label, dose ranging study to evaluate the safety and tolerance of CreaVax-RA in active rheumatoid arthritis patients with usual DMARDs;

2010/09/14;[1 screen]. Available at:

http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=1645 


Disclosure:

Y. B. Joo,
None;

J. E. Park,

JW CREAGENE,

3;

C. B. Choi,
None;

J. Choi,
None;

J. A. Jang,

JW CREAGENE,

3;

M. Heo,

JW CREAGENE,

3;

H. Y. Kim,

JW CREAGENE,

3;

H. S. Lee,
None;

Y. S. Bae,

JW CREAGENE,

1,

JW CREAGENE,

3;

S. C. Bae,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/phase-1-study-of-immunotherapy-using-autoantigen-loaded-dendritic-cells-in-patients-with-anti-citrullinated-peptide-antigen-positive-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology